{"classes":[{"categories":[{"measurements":[{"comment":"Median duration of response (DOR) could not be calculated. Upper and lower confidence interval for DOR could not be obtained using Kaplan-Meier estimates. Insufficient number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"Defined in participants experiencing CR or PR using RECIST 1.1, \"Lugano Criteria\" for malignant lymphoma or other tumor-specific criteria. Summarized statistically using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients enrolled into 1 of 3 cohorts based on CD4+ T-cell counts, who receive pembrolizumab IV over 30 minutes on day 1. Patients continue receiving their recommended combination antiretroviral therapy per established regimen. Cycles repeat every 21 days for up to 2 years or 35 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET/CT and blood sample collection throughout the trial. Patients may also undergo biopsies during screening and on study.\n\nAntiretroviral Therapy: Given PO\n\nBiopsy: Undergo biopsy\n\nBiospecimen Collection: Undergo blood sample collection\n\nComputed Tomography: Undergo CT or PET/CT\n\nPembrolizumab: Given IV\n\nPositron Emission Tomography: Undergo PET/CT","id":"OG000","title":"Cohorts 1-3 (Pembrolizumab and cART)"}],"paramType":"MEDIAN","populationDescription":"Analysis is based on all participants who received at least one dose of study drug. Participants without documented progression were censored at the last disease assessment date.\n\nPer the protocol, participants enrolled into Cohorts 1-3 were combined into one group for analysis. The number of participants enrolled to each cohort was not sufficient to perform subgroup analysis based on a CD4 count.","reportingStatus":"POSTED","timeFrame":"Interval between the date of first response (CR/PR) and the date of progression, assessed up to 2 years","title":"Duration of Response (Cohorts 1-3)","type":"SECONDARY","unitOfMeasure":"months"}